Rigel Pharmaceuticals Inc Total Liabilities
Rigel Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has total liabilities worth $95.42 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Rigel Pharmaceuticals Inc (RIGL) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rigel Pharmaceuticals Inc (1999–2025)
Total liabilities of Rigel Pharmaceuticals Inc from 1999 to 2025. This chart illustrates how Rigel Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Rigel Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cimsa Cimento Sanayi ve Ticaret AS
IS:CIMSA
|
Turkey | TL43.23 Billion |
|
Delong Composite Energy Group Co Ltd
SHE:000593
|
China | CN¥926.80 Million |
|
Fengfan Power
SHG:601700
|
China | CN¥4.80 Billion |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
China | CN¥848.12 Million |
|
Minerals 260 Ltd
AU:MI6
|
Australia | AU$16.95 Million |
|
Jiangsu Libert Inc
SHG:605167
|
China | CN¥2.53 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥1.62 Billion |
|
Jiajiayue Group Co Ltd
SHG:603708
|
China | CN¥9.56 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Rigel Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RIGL total assets.
Liquidity & Leverage Metrics
Rigel Pharmaceuticals Inc Total Liabilities Ratios Explained
Rigel Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rigel Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Rigel Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $122.11 Million | -24.01% |
| 2024-12-31 | $160.69 Million | +10.16% |
| 2023-12-31 | $145.87 Million | -1.37% |
| 2022-12-31 | $147.90 Million | +7.99% |
| 2021-12-31 | $136.95 Million | +79.37% |
| 2020-12-31 | $76.35 Million | -18.56% |
| 2019-12-31 | $93.75 Million | +220.72% |
| 2018-12-31 | $29.23 Million | +58.31% |
| 2017-12-31 | $18.46 Million | -20.09% |
| 2016-12-31 | $23.11 Million | -42.76% |
| 2015-12-31 | $40.37 Million | +55.92% |
| 2014-12-31 | $25.89 Million | +45.39% |
| 2013-12-31 | $17.81 Million | -14.99% |
| 2012-12-31 | $20.95 Million | -0.05% |
| 2011-12-31 | $20.96 Million | +1.91% |
| 2010-12-31 | $20.56 Million | -33.40% |
| 2009-12-31 | $30.88 Million | -22.21% |
| 2008-12-31 | $39.69 Million | +18.11% |
| 2007-12-31 | $33.61 Million | +29.20% |
| 2006-12-31 | $26.01 Million | -33.44% |
| 2005-12-31 | $39.08 Million | +47.35% |
| 2004-12-31 | $26.52 Million | +70.54% |
| 2003-12-31 | $15.55 Million | -17.72% |
| 2002-12-31 | $18.90 Million | +7.96% |
| 2001-12-31 | $17.51 Million | +14.78% |
| 2000-12-31 | $15.25 Million | -7.07% |
| 1999-12-31 | $16.41 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more